Press Releases

Press Releases

Date Title
02/09/18 Vaxart Provides Merger Update
02/07/18 Aviragen and Vaxart Amend Terms of Merger Agreement to Increase the Value for Aviragen Stockholders
Aviragen Stockholders to Own 49% of Combined Company, Up from 40% Under the Previous Agreement
02/06/18 Aviragen Adjourns Special Meeting of Stockholders Until February 9, 2018
Board of Directors Unanimously Recommends that Aviragen Stockholders Vote FOR the Vaxart Merger
01/31/18 Aviragen Provides New Information Supporting Vote FOR Vaxart Merger
Reiterates Transaction Represents Best Path Forward for Aviragen and ALL Stockholders CAS Group Has Not Articulated a Clear Plan and Has Now Changed its Stance to Emphasize Teslexivir (BTA074) ATLANTA , Jan. 31, 2018 (GLOBE NEWSWIRE) --   Aviragen Therapeutics, Inc.
01/31/18 Vaxart Announces its Oral Flu Vaccine Significantly Reduced Rate of Influenza Infection in Phase 2 Challenge Study
Vaxart Announces its Oral Flu Vaccine Significantly Reduced Rate of Influenza Infection in Phase 2 Challenge Study  
01/31/18 Vaxart Issues Statement Regarding Proposed Merger With Aviragen
01/26/18 Aviragen Comments on ISS Report
Vaxart Merger is the Result of an Extensive Review of Strategic Alternatives and is in the Best Interest of ALL Stockholders Aviragen Board of Directors Unanimously Recommends that Stockholders Vote FOR the Proposed Merger with Vaxart ATLANTA , Jan. 26, 2018 (GLOBE NEWSWIRE) -- Aviragen
01/24/18 Aviragen Therapeutics Issues Letter to Stockholders
Reiterates Benefits of Proposed Merger with Vaxart   Urges All Aviragen Stockholders to Vote FOR the Proposed Merger on the WHITE Proxy Card Today ATLANTA , Jan. 24, 2018 (GLOBE NEWSWIRE) --   Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today issued a letter to stockholders urging them to vote FOR
01/11/18 Aviragen Board Of Directors Unanimously Recommends That Stockholders Vote FOR The Proposed Merger With Vaxart
Transaction Creates a Leading Vaccine Company and Maximizes Value for Aviragen Stockholders Updated Investor Presentation Filed with Securities and Exchange Commission and Posted to Aviragen Website ATLANTA , Jan. 11, 2018 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc.